A photo of Christina Tarango.

Medical Director, Hemophilia Treatment Center

Associate Professor, UC Department of Pediatrics



Board Certified

Best Doctors logo

"I try to treat each patient the way I would want my family members to be cared for."

My Biography & Research


As a pediatric hematologist, I treat children with conditions such as hemophilia, von Willebrand disease, thrombosis (blood clots) and other blood conditions. I try to treat each patient the way I would want my family members to be cared for. It’s very important for patients and families to take an active role in their care and share in the decision-making.

I was influenced in my career choice by a wonderful pediatrician who cared for me when I was growing up. After I became a pediatrician, I chose the field of hematology because it’s so diverse and interesting. At Cincinnati Children’s, I enjoy working with our dedicated group of physicians as well as our excellent nurse care managers, social workers, child life specialists and other professionals who are so committed to supporting children with blood disorders.

In addition to patient care, I conduct research. My studies are focused on gaining a better understanding of thrombosis and its management in children. I am also involved with studies assessing different treatments for hemophilia, as well as evaluating the immune system in patients with hemophilia, both with and without inhibitors. Inhibitors are antibodies that can prevent treatments from working, which makes it more difficult to stop a bleeding episode.

Outside the hospital, I love spending time with my husband and daughter. I also enjoy traveling, reading and volunteering when I can.

Additional Languages


Research Interests

Pediatric bleeding disorders and thrombosis; quality improvement; medical education

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Thrombosis, Epidermolysis Bullosa EB, Hemophilia

Research Divisions

Hematology, Cancer and Blood Diseases

My Locations

My Education

MD: Stanford University School of Medicine, Stanford, CA, 2003.

Residency: Yale-New Haven Hospital, New Haven, CT, 2006.

Fellowship: University of Texas Southwestern Medical Center Dallas, Dallas, TX, 2009.

Certification: Pediatrics, 2006; Pediatric Hematology Oncology, 2011.

My Publications

Correlation among Hemolysis Biomarkers in Pediatric Patients Undergoing Extracorporeal Membrane Oxygenation. Ghaleb, S; Reagor, JA; Tarango, C; Benscoter, A; Smith, R; Byrnes, JW. Journal of Extra-Corporeal Technology. 2021; 53:125-129.

Pediatric May-Thurner Syndrome-Systematic review and individual patient data meta-analysis. Avila, L; Cullinan, N; White, M; Gaballah, M; Cahill, AM; Warad, D; Rodriguez, V; Tarango, C; Hoppmann, A; Nelson, S; et al. Journal of Thrombosis and Haemostasis. 2021; 19:1283-1293.

Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural). Shapiro, AD; Ragni, MV; Borhany, M; Abajas, YL; Tarantino, MD; Holstein, K; Croteau, SE; Liesner, R; Tarango, C; Carvalho, M; et al. Haemophilia. 2021; 27:49-59.

Enteral iron absorption in patients with recessive dystrophic epidermolysis bullosa. Augsburger, BD; Lucky, AW; Marathe, K; Tarango, C. Pediatric Dermatology. 2020; 37:817-820.

Non-transfusion-dependent β-Thalassemia Because of a Single β-Thalassemia Mutation and Coinherited α-Globin Gene Triplication: Need for Increased Awareness to Prevent Incorrect and Delayed Diagnosis. Gurunathan, A; Tarango, C; McGann, PT; Niss, O; Quinn, CT. Journal of Pediatric Hematology/Oncology. 2020; 42:e494-e496.

Pure red cell aplasia with isolated human herpes virus 6 infection of bone marrow in postcardiac transplant patient. Todd, K; Paulsen, G; Danziger-Isakov, L; Tarango, C. Pediatric Blood and Cancer. 2020; 67.

Antiphospholipid syndrome in pediatric patients. Tarango, C; Palumbo, JS. Current Opinion in Hematology. 2019; 26:366-371.

Treatment of Pediatric Venous Thromboembolism. Meier, KA; Tarango, C. Journal of hospital medicine (Online). 2019; 14:497-498.

Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. Gruppo, RA; Malan, D; Kapocsi, J; Nemes, L; Hay, CR M; Boggio, L; Chowdary, P; Tagariello, G; von Drygalski, A; Hua, F; et al. Journal of Thrombosis and Haemostasis. 2018; 16:1984-1993.

Clinical algorithm to manage anemia in epidermolysis bullosa. Simpson, B; Tarango, C; Lucky, AW. Pediatric Dermatology. 2018; 35:e319-e320.